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ECP in the treatment of GvHD. Better understanding of the
mechanism is crucial for reﬁning the use of this novel therapy.
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ECP may improve clinical status in acute or chronic GVHD
patients refractory to several lines of immunosuppression. From
September 2003, 12 patients, 2 pediatric (1c and 1 aGVHD) and 10
adults (9c and 1 aGVHD) were admitted to ECP courses. To date,
8/12 are evaluable. Three steps ECP procedures were performed:
a mean of 15,6 (10–54) ECP were carried out per patient, mean
treatment duration was 4,8 (1,5–18) months. Acute GVHD pa-
tients underwent ECP within 1 month from the onset, whereas the
delay was signiﬁcantly longer in cGVHD patients: 12,5 (12–16)
months. An intensive treatment was applied to maintain clinical
improvement during the tapering of the immunosuppressive ther-
apy. Haematological parameters were studied before every ECP.
Monthly, cytoﬂuorimetric analysis was carried out to detect the
CD4, CD8, CD4CD25, NK subsets, CD19 B lympho-
cytes, and VB TCR oligoclonal subpopulations. 8/8 patients
showed skin GVHD manifestations, 5/8 liver function impairment,
3/8 oral lichen, and 2/8 mild ocular GVHD. Signiﬁcant skin
improvement was observed in 6/8 patients while a partial liver
recovery was detectable in 1/5, oral lichen remained stable in 2/3
patients. Moderate lymphopenia, in particular due to the decreas-
ing in CD8 subset, was observed in 4/8 patients. Oligoclonal
expansion of some subfamilies as VB14 (5/8), VB5.1 (4/8), VB20
(3/8), and VB16 (2/8) was found in overall patients. Fast disappear-
ance of these T subsets seemed to correlate with initial response
rate to ECP, but the same subsets were not detectable in 2 patients
that had become ECP resistant. Absolute ECP-treated and rein-
fused T lymphocytes did not seem relevant to ECP response, as 0,6
(0,2-3) and 0,75 (0,2-2)x10E8/KG lymphocytes were respectively
reinfused in responsive and resistant patients. ECP procedures
were well tolerated without relevant side effects. In conclusion,
response to ECP was satisfactory in 6/8 patients with skin GVHD,
while, as expected from already published series of patients, low
response rate was observed in liver, ocular and oral disease.
Though our case-study is limited, a more intensive ECP schedule
and prolonged time of treatment, once a clinical improvement has
been obtained, might be useful to maintain the reached results.
However, ECP might be performed in more selected patients, in
particular in skin GVHD patients.
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RNA TRANSFECTED CORD BLOOD-DERIVED DENDRITIC CELLS GENER-
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Acute Lymphocytic Leukaemia (ALL) patients who relapse after
haematopoietic stem cell transplantation have few therapeutic op-
tions. An immunotherapeutic approach that enhances the graft
versus leukemia effect may improve their survival. We postulate
that cord blood (CB) CD34-derived dendritic cells (DC) will be
ideal source of DC for CB transplant recipients. In addition, we
propose using RNA as a source of antigen to induce T cell re-
sponses to poorly immunogenic tumors such as ALL. CD34 cells
can expand and differentiate into DC and function as professional
antigen presenting cells. We regularly achieve 	90% transfection
efﬁciency with 	90% cell viability when CD34-DC are electro-
porated with eGFP mRNA. Electroporation of CD34-DC with
ﬂu mRNA results in processing, translation and presentation of
epitopes by the DC, and killing by ﬂu-speciﬁc Cytotoxic T Lym-
phocytes (CTL). We have induced CTL using leukemic total RNA
from the HLA-A2 ALL Nalm-6 cell line. The CTL speciﬁcally
lysed 49 11% of Nalm-6 cells compared to less than 7% lysis of
autologous and allogeneic mononuclear cells (P  .03 and P 
.022, respectively). Interestingly, CTL generated from Nalm-6
total RNA were also able to lyse 16 5.4% of autologous survivin
mRNA transfected DC. CTL cultures consisted of 70% CD4 and
10–15% CD8 with less than 10% NK cells. To test the in vivo
efﬁcacy of these anti-leukemic CTL, we have established a NOD-
SCID mouse model of ALL from patient samples. By varying the
inocula of ALL cells, we have established a model of emerging
relapse. The consistent and predictable engraftment rates post
transplant will allow us to administer CTL at different time points
in vivo to test the efﬁcacy of the CTL at controlling in vivo
leukemic growth.
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Background: Although tacrolimus has been widely used for the
prophylaxis of GVHD, its optimal target blood level has not been
fully elucidated. This is a prospective single institute study evalu-
ating the effects of blood levels of tacrolimus on acute GVHD after
BMT from unrelated donor in a prophylaxis regimen consisting of
tacrolimus and methotrexate. Patients/Methods: Patients under-
going BMT from unrelated donor for hematological diseases in
Keio University Hospital were eligible. Tacrolimus was given at an
initial dose of 0.03 mg/kg by continuous intravenous infusion from
day 1, and its dose was adjusted to maintain its whole blood level
at 15–20 ng/ml. MTX was given at a dose of 15 mg/m2 on day 1,
and 10 mg/m2 on days 3 and 6, and additionally on day 11 if
possible. Results: Forty-four patients (median age: 41 years old)
were evaluable. Conditioning regimens were myeloablative in 38
and reduced intensity in 6 patients. HLA compatibility was sero-
logically/genotypically matched in 29, and mismatched in 15 pa-
tients, including serologically mismatched in 2 patients. Of the 44
patients, 41 patients (93.2%) achieved mean blood level 15–20
ng/ml in the ﬁrst week (day 0–7), 34 patients (77.3%) in the second
week (day 8–14), and 35 patients (79.4%) in the third week (day
15–21) post-transplant. Eighteen (41%) patients developed grades
II–IV acute GVHD, and only 3 patients (6.8%) developed grades
III–IV acute GVHD. HLA mismatch and blood level of tacrolimus
(mean concentration  15 ng/ml) in the second week post-trans-
plant were statistically identiﬁed as risk factors for developing
grades II–IV acute GVHD, while patient or donor age, MTX on
day 11, and blood levels of tacrolimus in other post-transplant
periods did not affect the incidence of acute GVHD. No serious
complications resulting in discontinuation of tacrolimus were ob-
served. Conclusions: Tacrolimus combined with methotrexate
could effectively prevent the development of acute GVHD, par-
ticularly severe acute GVHD, after BMT from unrelated donor by
maintaining its blood level above 15 ng/ml with strict monitoring
and dose adjustment.
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DELAYED GCV-MEDIATED ABLATION OF 
CD34-tk TRANSDUCED AND
SELECTED MURINE T CELLS PRESERVES GVL ACTIVITY WHILE MITI-
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We and others have previously demonstrated that delayed ad-
ministration of the prodrug ganciclovir (GCV) protects mice from
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